Dr. Bing Wang cofounded Amador Bioscience in 2018 through the merger of two start-up pharmaceutical companies. Today, Dr. Wang is Amador's Chairman and Chief Executive Officer.

Before Amador, Dr. Wang served as President of Lucid CPS and worked at Amgen, Abgenix, and MedImmune, a wholly-owned subsidiary of AstraZeneca.

During his time at AstraZeneca, Dr. Wang established and led a clinical pharmacology and pharmacometrics function that supported multiple research and development projects and contributed to more than 20 global regulatory submissions. He also managed and directed several multidisciplinary project teams in different therapeutic areas including hematology, oncology, and pulmonology.

Throughout his career, Dr. Wang has contributed to more than 100 publications and is listed as an inventor on 12 patents for drug development. He has been an invited speaker at numerous international conferences and has chaired symposiums and workshops at many international congresses. His academic collaborations include Peking University Health Science Center in China and a Johns Hopkins University collaboration with MedImmune on systems pharmacology.

Dr. Wang holds a Bachelor of Science in Materials Science from the University of Science and Technology of China, a Master of Science in Chemistry from the University of Kansas Lawrence, and a PhD in Pharmaceutical Sciences from the University of Nebraska Medical Center.